via University of Liverpool
Researchers from the University of Liverpool have created a biomedical compound that has the potential to stop the spread of breast cancer. A recently published paper details these early findings.
Scientists from the Chemistry and Biochemistry Departments at the University of Liverpool and Nanjing Medical School in China have discovered a possible way to block proteins produced in the body when a patient has cancer and which causes its spread to other parts of the body. This process, called metastasis, is largely responsible for patient deaths.
The major problem hindering the successful treatment of commonly occurring cancers is not the primary tumour which can usually be removed by surgery, but its spread to other organs of the body.
Prof Philip Rudland, Emeritus Professor in the University of Liverpool’s Department of Biochemistry, explained: “As a general rule, cancer that has spread is treated with chemotherapy, but this treatment can rarely be given without severely harming or becoming toxic to the patient. The importance of our work was to identify a specific and important target to attack, without toxic side effects.”
The University’s research team have in the past discovered that specific proteins are involved in the metastatic process; these proteins are different from those involved in the production of the primary tumour. One such example is a protein called ‘S100A4’, and is the protein chosen by the research team to target for the identification of chemical inhibitors of metastasis, using model systems of cells from the highly metastatic and incurable hormone receptor-free breast cancer.
Using these model systems, researchers at the University’s Department of Biochemistry discovered a novel compound that can specifically block the interaction of this metastasis-inducing protein S100A4 with its target inside the cell. Researchers in the Department of Chemistry then synthesised a simpler chemical and connected it to a warhead which stimulates the normal protein degrading machinery of a cell. This compound now works at very low doses to inhibit properties associated with metastasis, an improvement of over 20,000-fold on the original unarmed inhibitor, with virtually no toxic side effects. Moreover, in collaboration with Chinese researchers at Nanjing Medical School, they have shown that this compound inhibits metastasis in similar metastatic tumours in mice, suggesting a potential therapeutic role.
Dr Gemma Nixon, Senior Lecturer in Medicinal Chemistry at the University of Liverpool said: “This is an exciting breakthrough in our research. We now hope to take the next steps, and repeat this study in a large group of animals with similar metastatic cancers so that the efficacy and stability of the compounds can be thoroughly investigated and if necessary improved by further design and syntheses, prior to any clinical trials.”
“Significantly, this particular protein we’re investigating occurs in many different cancers, which could mean this approach may be valid for many other commonly occurring human cancers.”
The Latest Updates from Bing News
Go deeper with Bing News on:
- KOFIH commissions five health facilities in Volta, Oti Regions
The Korea Foundation for International Healthcare KOFIH has handed over five health facilities in the Volta and Oti Regions to the Ghana Health Service.
- Magnolia Berry Compound Shows Promise for Colon Cancer in Preclinical Models
The compound is found in the fruit of Schisandra chinensis ... Dr Murphy Wan , Senior-author, from the University of Portsmouth’s School of Pharmacy and Biomedical Sciences Existing research has shown ...
- Research suggests natural compound could be promising new alternative treatment for colon cancer
The compound is found in the fruit of Schisandra chinensis ... Senior author Dr. Murphy Wan from the University of Portsmouth's School of Pharmacy and Biomedical Sciences said, "Conventional cancer ...
- Biomedical Artificial Intelligence and Computational Modeling
Biomedical Artificial Intelligence and Computational Modeling are new emerging areas in biomedical engineering. These areas cover: Data analysis and interpretation: developing and applying algorithms ...
- New findings suggest life span can be increased by making cells less efficient at producing energy
A new study has shown that BAM15, a compound that makes mitochondria less efficient at producing energy, extended life span in fruit flies and was associated with less body fat and increased muscle ...
Go deeper with Bing News on:
Chemical inhibitors of metastasis
- Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the ...
- A New Type of Cancer Drug Shrinks Hard-to-Treat Tumors
Greg Thurber, a chemical engineer at the University of Michigan, looked into this conundrum. He began working on ADCs when studying how antibodies spread through the body ... newer topoisomerase ...
- Targeting cancer with small molecule kinase inhibitors
It is fair to say that the chemical challenge of making potent and selective inhibitors with good pharmacological ... that make established tumours and metastases so resistant to therapy.
- Novel drug combination shows promise for advanced HER2-negative breast cancer
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel ...
- Factors predictive of primary resistance (PrimRes) to immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial cancer (mUC).
Analysis of inactivating TSC1 and TSC2 alterations in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database.